CN1093762C - 9－羟基瑞培里酮脂肪酸酯类的含水悬浮液 - Google Patents

9－羟基瑞培里酮脂肪酸酯类的含水悬浮液 Download PDF

Info

Publication number
CN1093762C
CN1093762C CN97191494A CN97191494A CN1093762C CN 1093762 C CN1093762 C CN 1093762C CN 97191494 A CN97191494 A CN 97191494A CN 97191494 A CN97191494 A CN 97191494A CN 1093762 C CN1093762 C CN 1093762C
Authority
CN
China
Prior art keywords
agent
compositions
mixture
active component
hydroxyrisperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97191494A
Other languages
English (en)
Chinese (zh)
Other versions
CN1206347A (zh
Inventor
M·K·J·法兰西斯
R·C·A·恩布里什特斯
H·K·博尔吉斯
J·蒙巴利厄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1093762(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1206347A publication Critical patent/CN1206347A/zh
Application granted granted Critical
Publication of CN1093762C publication Critical patent/CN1093762C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN97191494A 1996-05-20 1997-05-12 9－羟基瑞培里酮脂肪酸酯类的含水悬浮液 Expired - Lifetime CN1093762C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
EP96201429.6 1996-05-20

Publications (2)

Publication Number Publication Date
CN1206347A CN1206347A (zh) 1999-01-27
CN1093762C true CN1093762C (zh) 2002-11-06

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97191494A Expired - Lifetime CN1093762C (zh) 1996-05-20 1997-05-12 9－羟基瑞培里酮脂肪酸酯类的含水悬浮液

Country Status (37)

Country Link
US (1) US6077843A (enExample)
EP (1) EP0904081B1 (enExample)
JP (1) JP3274687B2 (enExample)
KR (1) KR100358373B1 (enExample)
CN (1) CN1093762C (enExample)
AR (1) AR007194A1 (enExample)
AT (1) ATE208619T1 (enExample)
AU (1) AU715572B2 (enExample)
BG (1) BG62684B1 (enExample)
BR (1) BR9706824B8 (enExample)
CA (1) CA2236691C (enExample)
CY (2) CY2270B1 (enExample)
CZ (1) CZ291284B6 (enExample)
DE (2) DE69708284T2 (enExample)
DK (1) DK0904081T3 (enExample)
EA (1) EA000536B1 (enExample)
EE (1) EE03594B1 (enExample)
ES (1) ES2167745T3 (enExample)
FR (1) FR11C0035I2 (enExample)
HR (1) HRP970276B1 (enExample)
HU (2) HU224025B1 (enExample)
ID (1) ID16927A (enExample)
IL (1) IL124551A (enExample)
LU (1) LU91842I2 (enExample)
MX (1) MX9804816A (enExample)
MY (1) MY126302A (enExample)
NO (2) NO315931B1 (enExample)
NZ (1) NZ330369A (enExample)
PL (1) PL188309B1 (enExample)
PT (1) PT904081E (enExample)
SI (1) SI0904081T1 (enExample)
SK (1) SK284013B6 (enExample)
TR (1) TR199800923T2 (enExample)
TW (1) TW487572B (enExample)
UA (1) UA61898C2 (enExample)
WO (1) WO1997044039A1 (enExample)
ZA (1) ZA974331B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128436A1 (fr) * 2007-04-19 2008-10-30 Youxin Li Nouveaux composés pour le traitement de troubles psychotiques, procédés d'élaboration, et leurs utilisations

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
EP1317434A4 (en) * 2000-08-14 2005-06-22 Teva Pharma PREPARATION OF RISPERIDONE
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2494234C (en) * 2002-07-29 2009-10-27 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA2543242C (en) 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
HUE053904T2 (hu) 2007-12-19 2021-07-28 Janssen Pharmaceutica Nv Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2629775A4 (en) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2587527T3 (es) * 2011-05-31 2016-10-25 RAMAMOHAN RAO, Davuluri Preparación de 3-[2-[4-((6-fluoro-1,2-bencisoxazol-3-il)-l-piperidinil)-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4H-pirido[1,2 a]-primidin-4-ona (paliperidona) y palmitato de paliperidona
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016164218A1 (en) 2015-04-07 2016-10-13 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
AU2021386450B2 (en) 2020-11-30 2024-03-21 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
SMT202400075T1 (it) 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
MX2023006369A (es) 2020-11-30 2023-08-09 Janssen Pharmaceutica Nv Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona.
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CN1121719A (zh) * 1993-04-28 1996-05-01 詹森药业有限公司 瑞斯哌利酮双羟萘酸盐

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
AU694147B2 (en) * 1993-11-19 1998-07-16 Alkermes, Inc. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
PT833820E (pt) * 1995-06-06 2001-07-31 Aventis Pharmaceuticals Inc Av Derivados de benzisoxazol e indazol uteis como agentes antipsicoticos
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CN1121719A (zh) * 1993-04-28 1996-05-01 詹森药业有限公司 瑞斯哌利酮双羟萘酸盐

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128436A1 (fr) * 2007-04-19 2008-10-30 Youxin Li Nouveaux composés pour le traitement de troubles psychotiques, procédés d'élaboration, et leurs utilisations

Also Published As

Publication number Publication date
ATE208619T1 (de) 2001-11-15
EA199800531A1 (ru) 1998-12-24
BR9706824B8 (pt) 2015-02-18
HUS1100013I1 (hu) 2017-03-28
HUP9901319A3 (en) 1999-11-29
HU224025B1 (hu) 2005-05-30
US6077843A (en) 2000-06-20
AR007194A1 (es) 1999-10-13
PL188309B1 (pl) 2005-01-31
MX9804816A (es) 1998-10-31
FR11C0035I2 (fr) 2013-08-16
DE69708284D1 (de) 2001-12-20
AU2955997A (en) 1997-12-09
DK0904081T3 (da) 2002-02-25
KR19990067603A (ko) 1999-08-25
AU715572B2 (en) 2000-02-03
ZA974331B (en) 1998-11-19
NO315931B1 (no) 2003-11-17
CZ140198A3 (cs) 1999-04-14
CY2270B1 (en) 2003-07-04
NO981984D0 (no) 1998-04-30
LU91842I2 (fr) 2011-09-20
NO2011015I1 (no) 2011-09-19
CY2011011I1 (el) 2016-12-14
ID16927A (id) 1997-11-20
BG62684B1 (bg) 2000-05-31
IL124551A (en) 2001-08-26
EP0904081A1 (en) 1999-03-31
HUP9901319A2 (hu) 1999-08-30
FR11C0035I1 (enExample) 2011-07-10
EP0904081B1 (en) 2001-11-14
KR100358373B1 (ko) 2003-02-11
NO981984L (no) 1998-11-19
PL327995A1 (en) 1999-01-04
EA000536B1 (ru) 1999-10-28
TR199800923T2 (xx) 1999-09-21
TW487572B (en) 2002-05-21
JP3274687B2 (ja) 2002-04-15
CA2236691C (en) 2007-01-02
SK284013B6 (sk) 2004-08-03
SK62098A3 (en) 2000-04-10
WO1997044039A1 (en) 1997-11-27
UA61898C2 (en) 2003-12-15
BG102443A (en) 1999-06-30
CY2011011I2 (el) 2016-12-14
IL124551A0 (en) 1998-12-06
EE9800136A (et) 1998-10-15
CZ291284B6 (cs) 2003-01-15
DE69708284T2 (de) 2002-07-25
HRP970276A2 (en) 1998-04-30
NO2011015I2 (no) 2013-03-11
HRP970276B1 (en) 2002-04-30
EE03594B1 (et) 2002-02-15
MY126302A (en) 2006-09-29
NZ330369A (en) 2000-04-28
ES2167745T3 (es) 2002-05-16
CA2236691A1 (en) 1997-11-27
PT904081E (pt) 2002-04-29
BR9706824A (pt) 1999-03-23
CN1206347A (zh) 1999-01-27
HK1017852A1 (en) 1999-12-03
JP2000513718A (ja) 2000-10-17
DE122011100027I1 (de) 2011-11-17
SI0904081T1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
CN1093762C (zh) 9－羟基瑞培里酮脂肪酸酯类的含水悬浮液
CN1160074C (zh) 亚微细粒9-羟基雷士培力酮(Risperidone)脂肪酸酯类的含水悬浮液
US8293765B2 (en) Injectable depot formulation comprising crystals of iloperidone
US20220370359A1 (en) Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
HK1017852B (en) Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1053146

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20021106